Experienced in Paroxysmal Cold Hemoglobinuria

Dr. David A. Jacobsohn

Pediatric Hematology Oncology
2300 Childrens Plaza, 
Chicago, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Paroxysmal Cold Hemoglobinuria
2300 Childrens Plaza, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Jacobsohn is a Pediatric Hematologist Oncology provider in Chicago, Illinois. Dr. Jacobsohn is rated as an Experienced provider by MediFind in the treatment of Paroxysmal Cold Hemoglobinuria. His top areas of expertise are Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Hemoglobinopathy, Anemia, and Bone Marrow Transplant.

His clinical research consists of co-authoring 98 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Paroxysmal Cold Hemoglobinuria.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in IL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 3 Less Insurance Carriers -

Locations

2300 Childrens Plaza, Chicago, IL 60614

Additional Areas of Focus

Dr. Jacobsohn has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Multi-institutional Prospective Phase I Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
Multi-institutional Prospective Phase I Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
Enrollment Status: Recruiting
Publish Date: May 31, 2025
Intervention Type: Biological
Study Drug: Tumor Associated Antigen Lymphocytes (TAA-T)
Study Phase: Phase 1
Abatacept Combined With a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial
Abatacept Combined With a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial
Enrollment Status: Completed
Publish Date: July 17, 2024
Intervention Type: Drug
Study Drug: Abatacept
Study Phase: Phase 2
Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE Team) - Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease
Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE Team) - Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2023
Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients Affected by Haematological Disorders
Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients Affected by Haematological Disorders
Enrollment Status: Terminated
Publish Date: September 29, 2023
Intervention Type: Biological, Drug
Study Drugs: Rivogenlecleucel, Rimiducid
Study Phase: Phase 1/Phase 2
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Enrollment Status: Unknown
Publish Date: February 08, 2023
Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Enrollment Status: Active_not_recruiting
Publish Date: July 12, 2022
Intervention Type: Biological, Drug
Study Drugs: BPX-501 T Cells, Rimiducid
Study Phase: Phase 1/Phase 2
Development and Validation of a Symptoms Scale for Children With Chronic Graft-versus-Host Disease
Development and Validation of a Symptoms Scale for Children With Chronic Graft-versus-Host Disease
Enrollment Status: Completed
Publish Date: October 08, 2019
Markers of Inflammation in Hematopoietic Stem Cell Transplant
Markers of Inflammation in Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: August 30, 2019
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.
Enrollment Status: Terminated
Publish Date: May 17, 2019
Intervention Type: Drug
View 8 Less Clinical Trials

98 Total Publications

Advances in Gene Therapy for Sickle Cell Disease: From Preclinical Innovations to Clinical Implementation and Access Challenges.
Advances in Gene Therapy for Sickle Cell Disease: From Preclinical Innovations to Clinical Implementation and Access Challenges.
Journal: The CRISPR journal
Published: May 13, 2025
Similar Doctors
Experienced in Paroxysmal Cold Hemoglobinuria
Dr. Lisa Giordano
Pediatric Hematology Oncology
Experienced in Paroxysmal Cold Hemoglobinuria
Dr. Lisa Giordano
Pediatric Hematology Oncology
1901 W Harrison St, Stroger Hospital Of Cook County, 
Chicago, IL 
 (3.8 miles away)
312-864-4166
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lisa Giordano is a Pediatric Hematologist Oncology provider in Chicago, Illinois. Dr. Giordano is rated as an Experienced provider by MediFind in the treatment of Paroxysmal Cold Hemoglobinuria. Her top areas of expertise are Hemolytic Anemia, Sickle Cell Disease, Osteosarcoma, and Congenital Hemolytic Anemia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jacobsohn's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 14 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile